Cytokinetics presents pivotal aficamten data for rare heart disease
Cytokinetics released full trial results showing its drug aficamten improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.
The biotech company unveiled comprehensive data from its pivotal study of aficamten, a therapy targeting non-obstructive hypertrophic cardiomyopathy. Results indicated enhancements in how participants felt and in their ability to exercise. Some analysts described the observed benefits as modest. Cytokinetics intends to file an FDA submission before the year concludes, which could lead to the first approved treatment for this condition.
Why it matters
A new approved drug could address an unmet need for patients with a rare heart condition.
In this story
aficamtennon-obstructive hypertrophic cardiomyopathypivotal trialsymptom improvementexercise capacityFDA submissionrare heart disease
